With these benefits and challenges in mind, as well as the current need for sensitive cognitive testing in preclinical AD, this scoping review will provide an overview of available remote and unsupervised digital cognitive assessments used in individuals with no clinically identified cognitive decline, but with biomarker evidence for elevated levels of Aβ, or Aβ and tau. Here, MAPT is linked to Mental deterioration.